Atorvastatin Pretreatment in Cerebrovascular Events (APICES) After Flow Diverter Implantation

APICES trial is an investigator-initiated, multicenter, multicenter, randomized, double-blind, placebo-controlled clinical trial that plans to enroll 396 patients with a 1-year follow-up, including a neurovascular imaging examination \[digital subtraction angiography (DSA), CT angiography (CTA) or magnetic resonance angiography (MRA)\] at 6 months after index treatment. It was designed in compliance with the Declaration of Helsinki and the International Conference on Harmonization Good Clinical Practice guidelines. The study was approved by the Ethics Committee of Zhujiang Hospital of South Medical University (2024-KY-032-02) and registered at ClinicalTrials.gov (NCT06308952). The participants will be recruited from twelve advanced stroke centers in China.

NCT Number	NCT06308952
Lead Sponsor	Duan Chuanzhi Collaborators: Shenzhen Second People's Hospital, First Affiliated Hospital of Harbin Medical University, ZhuHai Hospital, First Hospital of Shijiazhuang City, Eighth Affiliated Hospital, Sun Yat-sen University, First Affiliated Hospital of Jinan University, Dongguan Kanghua Hospital, Beijing Tiantan Hospital, Guangdong 999 Brain Hospital, The First Affiliated Hospital of Zhengzhou University, First Affiliated Hospital of Chongqing Medical University, Dongguan People's Hospital, Xinqiao Hospital of Chongqing, Shanxi Cardiovascular Hospital, Peking Union Medical College Hospital, Tianjin Huanhu Hospital
Conditions	Cerebrovascular Event, Stent Stenosis, Ischemic Stroke, Hemorrhagic Stroke, Stent Thrombosis, Death, Brain, Endothelial Dysfunction
Enrollment	354 participants
Start Date	2024-07-30
Primary Completion	2027-12-01 (estimated)
Study Completion	2027-12-31 (estimated)
Updated on ClinicalTrials.gov	2026-03-03